Joseph Munn, Peter Austin, Clare Atzema, Stacey Butler, Candace McNaughton, Xuesong Wang, Andrea S Gershon
{"title":"调查COVID-19感染对慢性阻塞性肺疾病患者医疗保健利用的长期影响","authors":"Joseph Munn, Peter Austin, Clare Atzema, Stacey Butler, Candace McNaughton, Xuesong Wang, Andrea S Gershon","doi":"10.1016/j.chest.2025.02.043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with chronic obstructive pulmonary disease (COPD) are at elevated risk of severe outcomes following COVID-19 infection.</p><p><strong>Research questions: </strong>Does COVID-19 have a long-term impact on healthcare utilization (HCU) for individuals with COPD?</p><p><strong>Study design and methods: </strong>We conducted a retrospective matched cohort study using health administrative data from Ontario Canada, between April 2020 and June 2022. Individuals with physician-diagnosed COPD who received a COVID-19 PCR test were included. COVID-19 positive and negative patients were matched on age, sex, vaccination status, PCR test date, and a propensity score. Patients were followed from the end of the acute infection period (12-weeks post-PCR) until the study end date. Per-person-year HCU rates were captured and compared. Analyses were stratified by COVID-19 variant eras (Wild-Type/Alpha/Beta, Delta, and Omicron) and vaccination status (0, 1, 2, and ≥3).</p><p><strong>Results: </strong>We identified 31,540 matched pairs. Mean age was 66.4 years and 49.9% were male. Individuals with positive COVID-19 tests had 9% higher HCU rates than those who tested negative (rate ratio [RR]: 1.09 CI: 1.067-1.127). Stratifying by variant, Wild-Type/Alpha/Beta and Omicron variants had 16% (RR: 1.16, CI: 1.119-1.22) and 5% (RR: 1.051, CI: 1.01-1.092) higher HCU rates respectively. Individuals with ≥3 vaccinations did not have elevated rates of HCU (RR: 1.03, CI: 0.981-1.081) compared to those who tested negative.</p><p><strong>Interpretation: </strong>COVID-19 positive COPD patients had significantly greater long-term HCU usage. Although Omicron has been considered milder than previous variants, it was still associated with significantly elevated long-term HCU. Individuals with ≥3 vaccinations who tested positive for COVID-19 had similar HCU rates to those who tested negative, suggesting that vaccinations can reduce long-term healthcare utilization.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the Long-Term Effects of COVID-19 Infection on Healthcare Utilization in Individuals with Chronic Obstructive Pulmonary Disease.\",\"authors\":\"Joseph Munn, Peter Austin, Clare Atzema, Stacey Butler, Candace McNaughton, Xuesong Wang, Andrea S Gershon\",\"doi\":\"10.1016/j.chest.2025.02.043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Individuals with chronic obstructive pulmonary disease (COPD) are at elevated risk of severe outcomes following COVID-19 infection.</p><p><strong>Research questions: </strong>Does COVID-19 have a long-term impact on healthcare utilization (HCU) for individuals with COPD?</p><p><strong>Study design and methods: </strong>We conducted a retrospective matched cohort study using health administrative data from Ontario Canada, between April 2020 and June 2022. Individuals with physician-diagnosed COPD who received a COVID-19 PCR test were included. COVID-19 positive and negative patients were matched on age, sex, vaccination status, PCR test date, and a propensity score. Patients were followed from the end of the acute infection period (12-weeks post-PCR) until the study end date. Per-person-year HCU rates were captured and compared. Analyses were stratified by COVID-19 variant eras (Wild-Type/Alpha/Beta, Delta, and Omicron) and vaccination status (0, 1, 2, and ≥3).</p><p><strong>Results: </strong>We identified 31,540 matched pairs. Mean age was 66.4 years and 49.9% were male. Individuals with positive COVID-19 tests had 9% higher HCU rates than those who tested negative (rate ratio [RR]: 1.09 CI: 1.067-1.127). Stratifying by variant, Wild-Type/Alpha/Beta and Omicron variants had 16% (RR: 1.16, CI: 1.119-1.22) and 5% (RR: 1.051, CI: 1.01-1.092) higher HCU rates respectively. Individuals with ≥3 vaccinations did not have elevated rates of HCU (RR: 1.03, CI: 0.981-1.081) compared to those who tested negative.</p><p><strong>Interpretation: </strong>COVID-19 positive COPD patients had significantly greater long-term HCU usage. Although Omicron has been considered milder than previous variants, it was still associated with significantly elevated long-term HCU. Individuals with ≥3 vaccinations who tested positive for COVID-19 had similar HCU rates to those who tested negative, suggesting that vaccinations can reduce long-term healthcare utilization.</p>\",\"PeriodicalId\":9782,\"journal\":{\"name\":\"Chest\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chest\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.chest.2025.02.043\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.02.043","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Investigating the Long-Term Effects of COVID-19 Infection on Healthcare Utilization in Individuals with Chronic Obstructive Pulmonary Disease.
Background: Individuals with chronic obstructive pulmonary disease (COPD) are at elevated risk of severe outcomes following COVID-19 infection.
Research questions: Does COVID-19 have a long-term impact on healthcare utilization (HCU) for individuals with COPD?
Study design and methods: We conducted a retrospective matched cohort study using health administrative data from Ontario Canada, between April 2020 and June 2022. Individuals with physician-diagnosed COPD who received a COVID-19 PCR test were included. COVID-19 positive and negative patients were matched on age, sex, vaccination status, PCR test date, and a propensity score. Patients were followed from the end of the acute infection period (12-weeks post-PCR) until the study end date. Per-person-year HCU rates were captured and compared. Analyses were stratified by COVID-19 variant eras (Wild-Type/Alpha/Beta, Delta, and Omicron) and vaccination status (0, 1, 2, and ≥3).
Results: We identified 31,540 matched pairs. Mean age was 66.4 years and 49.9% were male. Individuals with positive COVID-19 tests had 9% higher HCU rates than those who tested negative (rate ratio [RR]: 1.09 CI: 1.067-1.127). Stratifying by variant, Wild-Type/Alpha/Beta and Omicron variants had 16% (RR: 1.16, CI: 1.119-1.22) and 5% (RR: 1.051, CI: 1.01-1.092) higher HCU rates respectively. Individuals with ≥3 vaccinations did not have elevated rates of HCU (RR: 1.03, CI: 0.981-1.081) compared to those who tested negative.
Interpretation: COVID-19 positive COPD patients had significantly greater long-term HCU usage. Although Omicron has been considered milder than previous variants, it was still associated with significantly elevated long-term HCU. Individuals with ≥3 vaccinations who tested positive for COVID-19 had similar HCU rates to those who tested negative, suggesting that vaccinations can reduce long-term healthcare utilization.
期刊介绍:
At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.